KAIROS PHARMA LTD (KAPA) Fundamental Analysis & Valuation

NYSEARCA:KAPA • US48301N1046

Current stock price

0.567 USD
+0 (+0.35%)
At close:
0.59 USD
+0.02 (+4.06%)
After Hours:

This KAPA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. KAPA Profitability Analysis

1.1 Basic Checks

  • In the past year KAPA has reported negative net income.
  • In the past year KAPA has reported a negative cash flow from operations.
  • KAPA had negative earnings in each of the past 5 years.
  • In the past 5 years KAPA reported 4 times negative operating cash flow.
KAPA Yearly Net Income VS EBIT VS OCF VS FCFKAPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 0 -1M -2M -3M -4M -5M

1.2 Ratios

  • KAPA has a Return On Assets of -83.29%. This is in the lower half of the industry: KAPA underperforms 70.10% of its industry peers.
  • Looking at the Return On Equity, with a value of -85.90%, KAPA is in line with its industry, outperforming 47.57% of the companies in the same industry.
Industry RankSector Rank
ROA -83.29%
ROE -85.9%
ROIC N/A
ROA(3y)-105.4%
ROA(5y)-138.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KAPA Yearly ROA, ROE, ROICKAPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 100 -100 -200

1.3 Margins

  • KAPA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KAPA Yearly Profit, Operating, Gross MarginsKAPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. KAPA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KAPA has more shares outstanding
  • KAPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KAPA Yearly Shares OutstandingKAPA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 5M 10M 15M 20M
KAPA Yearly Total Debt VS Total AssetsKAPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 2M 4M 6M

2.2 Solvency

  • KAPA has an Altman-Z score of 31.66. This indicates that KAPA is financially healthy and has little risk of bankruptcy at the moment.
  • KAPA's Altman-Z score of 31.66 is amongst the best of the industry. KAPA outperforms 92.82% of its industry peers.
  • There is no outstanding debt for KAPA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 31.66
ROIC/WACCN/A
WACCN/A
KAPA Yearly LT Debt VS Equity VS FCFKAPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 2M -2M 4M 6M

2.3 Liquidity

  • A Current Ratio of 27.07 indicates that KAPA has no problem at all paying its short term obligations.
  • KAPA has a Current ratio of 27.07. This is amongst the best in the industry. KAPA outperforms 97.09% of its industry peers.
  • KAPA has a Quick Ratio of 27.07. This indicates that KAPA is financially healthy and has no problem in meeting its short term obligations.
  • KAPA has a Quick ratio of 27.07. This is amongst the best in the industry. KAPA outperforms 97.09% of its industry peers.
Industry RankSector Rank
Current Ratio 27.07
Quick Ratio 27.07
KAPA Yearly Current Assets VS Current LiabilitesKAPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. KAPA Growth Analysis

3.1 Past

  • The earnings per share for KAPA have decreased strongly by -38.63% in the last year.
EPS 1Y (TTM)-38.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, KAPA will show a very strong growth in Earnings Per Share. The EPS will grow by 49.66% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.87%
EPS Next 2Y-30.82%
EPS Next 3Y-21.94%
EPS Next 5Y49.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KAPA Yearly Revenue VS EstimatesKAPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 200M 400M 600M 800M
KAPA Yearly EPS VS EstimatesKAPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. KAPA Valuation Analysis

4.1 Price/Earnings Ratio

  • KAPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KAPA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KAPA Price Earnings VS Forward Price EarningsKAPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KAPA Per share dataKAPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

  • KAPA's earnings are expected to decrease with -21.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.82%
EPS Next 3Y-21.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KAPA Dividend Analysis

5.1 Amount

  • No dividends for KAPA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KAPA Fundamentals: All Metrics, Ratios and Statistics

KAIROS PHARMA LTD

NYSEARCA:KAPA (5/1/2026, 5:31:42 PM)

After market: 0.59 +0.02 (+4.06%)

0.567

+0 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-31
Earnings (Next)N/A
Inst Owners4%
Inst Owner Change0%
Ins Owners35.18%
Ins Owner Change0%
Market Cap12.14M
Revenue(TTM)N/A
Net Income(TTM)-5.45M
Analysts82.22
Price Target9.18 (1519.05%)
Short Float %1.15%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.81%
Min EPS beat(2)-28.68%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-32.77%
Min EPS beat(4)-56.86%
Max EPS beat(4)-2.94%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8%
PT rev (3m)8%
EPS NQ rev (1m)6.25%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)-5.05%
EPS NY rev (3m)-5.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.91
P/tB 1.93
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.3
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -83.29%
ROE -85.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-105.4%
ROA(5y)-138.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.07
Quick Ratio 27.07
Altman-Z 31.66
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-17.87%
EPS Next 2Y-30.82%
EPS Next 3Y-21.94%
EPS Next 5Y49.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-129.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-64.14%
EBIT Next 3Y-82.15%
EBIT Next 5YN/A
FCF growth 1Y13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13%
OCF growth 3YN/A
OCF growth 5YN/A

KAIROS PHARMA LTD / KAPA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KAIROS PHARMA LTD (KAPA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KAPA.


What is the valuation status of KAIROS PHARMA LTD (KAPA) stock?

ChartMill assigns a valuation rating of 0 / 10 to KAIROS PHARMA LTD (KAPA). This can be considered as Overvalued.


Can you provide the profitability details for KAIROS PHARMA LTD?

KAIROS PHARMA LTD (KAPA) has a profitability rating of 0 / 10.


What is the financial health of KAIROS PHARMA LTD (KAPA) stock?

The financial health rating of KAIROS PHARMA LTD (KAPA) is 8 / 10.


What is the earnings growth outlook for KAIROS PHARMA LTD?

The Earnings per Share (EPS) of KAIROS PHARMA LTD (KAPA) is expected to decline by -17.87% in the next year.